Nutriband inc. reports record revenue up 118% yoy in q3

Orlando, fl / accesswire / december 5, 2022 / nutriband inc. (nasdaq:ntrb) (nasdaq:ntrbw), a developer of transdermal pharmaceutical products, today announced financial and operational results for the third quarter ended october 31, 2022. key highlights: generated record quarterly revenue of $620,000, up 118% over q3 2021 revenue for nine-months ended october 31, 2022, was $1,552,074, up 67% year-over-year continued to expand aversa™ intellectual property portfolio with patents now issued in 44 countries; aversa™ patent coverage includes the u.s., canada, europe, japan, korea, mexico, australia, and russia, with patents pending in china demonstrated with kindeva drug delivery enhanced abuse-deterrent characteristics for aversa fentanyl applied for dual listing on upstream stockholders' equity of $9.7 million as of october 31, 2022 "once again, we have had a record quarter for our revenue generating subsidiaries.
NTRB Ratings Summary
NTRB Quant Ranking